Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Jan;33(1):108–109. doi: 10.1128/aac.33.1.108

Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori.

A E Simor 1, S Ferro 1, D E Low 1
PMCID: PMC171430  PMID: 2712542

Abstract

The in vitro susceptibilities of 56 clinical isolates of Campylobacter pylori to six new fluoroquinolones and other oral antimicrobial agents were determined by an agar dilution technique. Ciprofloxacin was the most active of the fluoroquinolones (MIC for 90% of strains tested [MIC90], 0.05 microgram/ml). Other fluoroquinolones had variable activities, although most isolates were moderately susceptible to fleroxacin (MIC90, 4 micrograms/ml) and lomefloxacin (MIC90, 4 micrograms/ml).

Full text

PDF
108

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen J. J., Andersen L. P. In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics. Acta Pathol Microbiol Immunol Scand B. 1987 Apr;95(2):147–149. doi: 10.1111/j.1699-0463.1987.tb03103.x. [DOI] [PubMed] [Google Scholar]
  2. Blaser M. J. Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease. Gastroenterology. 1987 Aug;93(2):371–383. doi: 10.1016/0016-5085(87)91028-6. [DOI] [PubMed] [Google Scholar]
  3. Buck G. E., Gourley W. K., Lee W. K., Subramanyam K., Latimer J. M., DiNuzzo A. R. Relation of Campylobacter pyloridis to gastritis and peptic ulcer. J Infect Dis. 1986 Apr;153(4):664–669. doi: 10.1093/infdis/153.4.664. [DOI] [PubMed] [Google Scholar]
  4. Glupczynski Y., Labbe M., Burette A., Delmee M., Avesani V., Bruck C. Treatment failure of ofloxacin in Campylobacter pylori infection. Lancet. 1987 May 9;1(8541):1096–1096. doi: 10.1016/s0140-6736(87)90527-7. [DOI] [PubMed] [Google Scholar]
  5. Goodwin C. S., Blake P., Blincow E. The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrob Chemother. 1986 Mar;17(3):309–314. doi: 10.1093/jac/17.3.309. [DOI] [PubMed] [Google Scholar]
  6. Hooper D. C., Wolfson J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Humphreys H., Bourke S., Dooley C., McKenna D., Power B., Keane C. T., Sweeney E. C., O'Moráin C. Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial. Gut. 1988 Mar;29(3):279–283. doi: 10.1136/gut.29.3.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lambert T., Mégraud F., Gerbaud G., Courvalin P. Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents. Antimicrob Agents Chemother. 1986 Sep;30(3):510–511. doi: 10.1128/aac.30.3.510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Marshall B. J., Armstrong J. A., Francis G. J., Nokes N. T., Wee S. H. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion. 1987;37 (Suppl 2):16–30. doi: 10.1159/000199555. [DOI] [PubMed] [Google Scholar]
  10. Marshall B. J., McGechie D. B., Rogers P. A., Glancy R. J. Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust. 1985 Apr 15;142(8):439–444. doi: 10.5694/j.1326-5377.1985.tb113444.x. [DOI] [PubMed] [Google Scholar]
  11. McNulty C. A., Dent J., Wise R. Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents. Antimicrob Agents Chemother. 1985 Dec;28(6):837–838. doi: 10.1128/aac.28.6.837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. McNulty C. A., Gearty J. C., Crump B., Davis M., Donovan I. A., Melikian V., Lister D. M., Wise R. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) 1986 Sep 13;293(6548):645–649. doi: 10.1136/bmj.293.6548.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rauws E. A., Langenberg W., Houthoff H. J., Zanen H. C., Tytgat G. N. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology. 1988 Jan;94(1):33–40. [PubMed] [Google Scholar]
  14. Shungu D. L., Nalin D. R., Gilman R. H., Gadebusch H. H., Cerami A. T., Gill C., Weissberger B. Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents. Antimicrob Agents Chemother. 1987 Jun;31(6):949–950. doi: 10.1128/aac.31.6.949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Stone J. W., Wise R., Donovan I. A., Gearty J. Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach. J Antimicrob Chemother. 1988 Jul;22(1):92–93. doi: 10.1093/jac/22.1.92. [DOI] [PubMed] [Google Scholar]
  16. Van Caekenberghe D. L., Breyssens J. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori). Antimicrob Agents Chemother. 1987 Sep;31(9):1429–1430. doi: 10.1128/aac.31.9.1429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES